Building the infrastructure for trustworthy trials.
Dixit is an imaging Clinical Research Organisation (CRO) powered by WIDEN specialising in the management of clinical imaging in international multicentre trials.
From a Turin research idea to a European imaging CRO.
Established in 2011 as an academic spin-off from the University of Turin (opens in a new tab) and the Institute of Nuclear Physics (INFN) (opens in a new tab), the company was founded with a clear objective: to transform clinical imaging from a technical-operational process into a strategic scientific lever in drug development.
We operate as an independent CRO, combining expertise in quantitative imaging, medical physics, data governance and regulatory compliance to ensure that every clinical trial is underpinned by robust, reproducible and defensible data.
Our mission is clear: to improve clinical research through reliable, consistent imaging data that is ready for statistical analysis and regulatory submission. For us, imaging is not merely an ancillary tool, but an operational framework upon which critical clinical decisions are based.
The proprietary WIDEN platform (Web-based Imaging and Diagnosis Exchange Network) embodies this scientific approach in technological terms. The result of over a decade of research, development and collaboration with clinical groups and international scientific centres, WIDEN is designed to support complex multicentre studies in oncology, haematology, nuclear medicine and other imaging-intensive fields.
In a context where the methodological quality of data can determine the outcome of a study, Dixit operates as a specialist CRO and scientific partner, ensuring the control, consistency and integrity of imaging throughout the entire trial lifecycle.
To advance clinical imaging governance through scientific rigour and controlled operational workflows.
To govern clinical imaging in multicentre trials through controlled, traceable
and scientifically rigorous workflows that improve data consistency, endpoint
reliability and regulatory readiness.
Powered by WIDEN, our proprietary imaging core lab platform, we help
sponsors transform imaging operations into scalable and inspection-ready
clinical infrastructures.
Building the future of imaging governance for multicentre clinical trials.
We see a future where clinical imaging is fully standardised, quantitative and
operationally governed — enabling faster, more reliable and data-driven
therapeutic development worldwide.
We believe imaging should not function as a fragmented technical process, but
as a strategic clinical infrastructure supporting confident regulatory and clinical
decision-making.
The people behind the science.
A multidisciplinary team of physicists, clinicians and engineers who shape every imaging protocol, review workflow and quality standard we deliver.
Alexandru Stancu, PhD
Co-founder of Dixit, he leads the strategic development of WIDEN. With a background in electronic and computer engineering, he is responsible for the platform’s technical and methodological decisions.
Piergiorgio Cerello, PhD
Co-founder with many years’ experience in analysing large datasets and modelling algorithms for quantitative imaging. He brings unique expertise from high-profile international scientific projects.
Stéphane Chauvie, PhD
Co-founder medical physicist, with internationally recognised contributions to PET standardisation and biomarker development.
Dr. Andrea Gallamini, MD
Co-founder and associate professor with established experience in clinical oncology and international scientific committees.
Fifteen years of building imaging infrastructure.
The milestones that took us from a research idea to an imaging CRO trusted across a network of clinical sites.
Founded in Turin
A group of medical physicists and clinicians set out to bring scientific rigour to imaging in clinical trials.
First WIDEN core lab platform
Our internal workflow tooling matured into WIDEN, a dedicated platform for standardised imaging review and archiving.
International multicentre expansion
WIDEN scaled to support distributed multicentre studies across a growing network of qualified imaging sites.
ISO 9001 certification
Formalised our quality management system, embedding controlled processes across every imaging study we run.
Global imaging workflows
WIDEN scaled to support distributed multicentre studies across a growing network of qualified imaging sites.
Quantitative imaging & radiomics
Expanded scientific capabilities into radiomics, dosimetry and radiopharma support for advanced trial designs.
Next-generation WIDEN platform
Today WIDEN connects an international network of sites, sponsors and reviewers on a single traceable platform.
Built to be inspection-ready.
Our quality, security and regulatory frameworks are independently certified and audited — so the data we deliver holds up to scrutiny.
Certified quality management system governing every imaging workflow end to end.
Data protection by design, with pseudonymisation and controlled access across the network.
Processes designed around Good Clinical Practice to support regulated clinical research.
Cooperative groups and academic centres.
The institutions whose trials run on WIDEN. Sponsor identities stay confidential; these are the scientific groups whose work is already public.
Methodology you can read.
Our platform and our standardisation methods have been through peer review, and the trials that ran on them have published their results. See the full list.
- Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial (opens in a new tab)
- Metabolic heterogeneity-based radiomic model predicts treatment outcomes of primary mediastinal B-cell lymphoma patients in the IELSG37 study (opens in a new tab)
- Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi (opens in a new tab)
- Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub-Study of the FOLL12 Trial (opens in a new tab)
- Overall survival and quality of life with 177Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial (opens in a new tab)
- Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial (opens in a new tab)
Put this team behind your next trial.
You’ve seen the people, the milestones and the certifications behind Dixit. When you’re ready, the same scientists who built WIDEN will help you design imaging endpoints, qualify sites and keep every read inspection-ready.